Alterations in circulating osteoimmune factors may be responsible for high bone resorption rate in HIV-infected children and adolescents

AIDS

Volumn 21, Issue 9, 2007, Pages 1129-1135

  Mora, Stefano ^a   Zamproni, Ilaria ^a   Cafarelli, Laura ^b   Giacomet, Vania ^b   Erba, Paola ^b   Zuccotti, Gianvincenzo ^b   Viganò, Alessandra ^b  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

Bone metabolism; Bone resorption; HIV infected children; Osteoprotegerin; RANK ligand

Indexed keywords

ALKALINE PHOSPHATASE; AMINO TERMINAL TELOPEPTIDE; EFAVIRENZ; LAMIVUDINE; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PROTEINASE INHIBITOR; STAVUDINE; TENOFOVIR;

ADOLESCENT; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG SUBSTITUTION; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; OSTEOLYSIS; PRIORITY JOURNAL;

ADOLESCENT; ALKALINE PHOSPHATASE; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BIOLOGICAL MARKERS; BONE DENSITY; BONE RESORPTION; CHILD; CHILD, PRESCHOOL; COLLAGEN TYPE I; FEMALE; HIV INFECTIONS; HUMANS; LONGITUDINAL STUDIES; MALE; OSTEOPROTEGERIN; PEPTIDES; PROSPECTIVE STUDIES; RANK LIGAND;

EID: 34248545780     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32810c8ccf     Document Type: Article

References (30)

1. O'Brien KO, Razavi M, Henderson RA, Caballero B, Ellis KJ. Bone mineral content in girls perinatally infected with HIV. Am J Clin Nutr 2001; 73:821-826.
2. Mora S, Sala N, Bricalli D, Zuin G, Chiumello G, Viganò A. Bone mineral loss through increased bone turnover in HIV-infected children treated with highly active antiretroviral therapy. AIDS 2001; 15:1823-1829.
3. Arpadi SM, Horlick M, Thornton J, Cuff PA, Wang J, Kotler DP. Bone mineral content is lower in prepubertal HIV-infected children. J Acquir Immune Defic Syndr 2002; 29:450-454.
4. Arpadi S, Horlick M, Shane E. Metabolic bone disease in human immunodeficiency virus-infected children. J Clin Endocrinol Metab 2004; 89:21-23.
5. Mora S, Zamproni I, Beccio S, Bianchi R, Giacomet V, Viganò A. Longitudinal changes of bone mineral density and metabolism in antiretroviral-treated human immunodeficiency virus-infected children. J Clin Endocrinol Metab 2004; 89:24-28.
6. Jacobson DL, Spiegelman D, Duggan C, Weinberg GA, Bechard L, Furuta L, et al. Predictors of bone mineral density in human immunodeficiency virus-1 infected children. J Pediatr Gastroenterol Nutr 2005; 41:339-346.
7. Giacomet V, Mora S, Martelli L, Merlo M, Sciannamblo M, Viganò A. A 12-month treatment with tenofovir does not impair bone mineral accrual in HIV-infected children. J Acquir Immune Defic Syndr 2005; 40:448-450.
8. Rosso R, Vignolo M, Parodi A, Di Biagio A, Sormani MP, Bassetti M, et al. Bone quality in perinatally HIV-infected children: role of age, sex, growth, HIV infection, and antiretroviral therapy. AIDS Res Hum Retroviruses 2005; 21:927-932.
9. Gafni RI, Hazra R, Reynolds JC, Maldarelli F, Tullio AN, DeCarlo E, et al. Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy: impact on bone mineral density in HIV-infected children. Pediatrics 2006; 118:e711-e718.
10. Aubin JE, Heersche JNM. Bone cell biology: osteoblasts, osteocytes, and osteoclasts. In: Glorieux FH, Pettifor JM, Jüppner H, editors. Pediatric bone. Biology and diseases. San Diego: Academic Press; 2003. pp. 43-75.
11. Parfitt AM, Travers R, Rauch F, Glorieux FH. Structural and cellular changes during bone growth in healthy children. Bone 2000; 27:487-494.
12. Glorieux FH, Travers R, Taylor A, Bowen JR, Rauch F, Norman M, et al. Normative data for iliac bone histomorphometry in growing children. Bone 2000; 26:103-109.
13. Schönau E, Rauch F. Biochemical markers of bone metabolism. In: Glorieux FH, Pettifor JM, Jüppner H, editors. Pediatric bone. Biology and diseases. San Diego: Academic Press; 2003. pp. 339-357.
14. Tan MB, Nelson RP, James-Yarish M, Emmanuel PJ, Schurman SJ. Bone metabolism in children with human immunodeficiency virus infection receiving highly active anti-retroviral therapy including a protease inhibitor. J Pediatr 2001; 139: 447-451.
15. Zamboni G, Antoniazzi F, Bertoldo F, Lauriola S, Antozzi L, Tatò L. Altered bone metabolism in children infected with human immunodeficiency virus. Acta Paediatr 2003; 92:12-16.
16. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997; 89:309-319.
17. Hsu H, Lacey DL, Dunstan CR, Solovyev I, Colombero A, Timms E, et al. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci U S A 1999; 96:3540-3545.
18. Lacey DL, Timms E, Tan H-L, Kelly MJ, Dunstan CR, Burgess T, et al. Osteoprotegerin (OPG) ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998; 93:165-176.
19. Teitelbaum SL. Bone resorption by osteoclasts. Science 2000; 289:1504-1508.
20. Rogers, Eastell R. Circulating osteoprotegerin and receptor activator for nuclear factor kappa B ligand: clinical utility in metabolic bone disease assessment. J Clin Endocrinol Metab 2005; 90:6323-6331.
21. Cacciari E, Milani S, Balsamo A, Spada E, Bona G, Cavallo L, et al. Italian cross-sectional growth charts for height, weight and BMI (2 to 20 yr). J Endocrinol Invest 2006; 29:581-593.
22. Tanner JM, Whitehouse RH. Clinical longitudinal standards for height, weight, height velocity and weight velocity and stages of puberty. Arch Dis Child 1976; 51:170-179.
23. Mora S, Prinster C, Proverbio MC, Bellini A, de Poli SC, Weber G, et al. Urinary markers of bone turnover in healthy children and adolescents: age-related changes and effect of puberty. Calcif Tissue Int 1998; 63:369-374.
24. Seminari E, Castagna A, Soldarini A, Galli L, Fusetti G, Dorigatti F, et al. Osteoprotegerin and bone turnover markers in heavily pretreated HIV-infected patients. HIV Med 2005; 6:145-150.
25. Konishi M, Takahashi K, Yoshimoto E, Uno K, Kasahara K, Mikasa K. Association between osteopenia/osteoporosis and the serum RANKL in HIV-infected patients. AIDS 2005; 19:1240-1241.
26. Andreson DM, Maraskovsky E, Billingsley WL, Dougall WC, Tometsko M, Roux ER, et al. A homologue of the TNF receptor and its ligand enhance T cell growth and dendritic cell function. Nature 1997; 390:175-179.
27. Dougall WC, Glaccum M, Charrier K, Rohrbach K, Brasel K, De Smedt T, et al. RANK is essential for osteoclast and lymph node development. Genes Dev 1999; 18:2412-2424.
28. Fakruddin JM, Laurence J. HIV envelope gp120-mediated regulation of osteoclastogenesis via receptor activator of nuclear faktor κB ligand (RANKL) secretion and its modulation by certain HIV protease inhibitors through interferong-γ/RANKL cross-talk. J Biol Chem 2003; 278:48251-48258.
29. Wang MW-H, Wei S, Faccio R, Takeshita S, Tebas P, Powderly WG, et al. The HIV protease inhibitor ritonavir blocks osteoclastogenesis and function by impairing RANKL-induced signaling. J Clin Invest 2004; 114:206-213.
30. Viganò A, Aldrovandi GM, Giacomet V, Merlo M, Martelli L, Beretta S, et al. Improvement in dyslipidaemia after switching stavudine to tenofovir and replacing protease inhibitors with efavirenz in HIV-infected children. Antiviral Ther 2005; 10:917-924.